comparemela.com

Tragiannidisa Acinetobacter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S., it is estimated there are more than 40,000 cases of Acinetobacter each year and approximately 40.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.